The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
BREAKWATER: Analysis of first-line encorafenib + cetuximab + chemotherapy in BRAF V600E-mutant metastatic colorectal cancer.
 
Scott Kopetz
Stock and Other Ownership Interests - Frontier Medicines; Lutris; Navire
Consulting or Advisory Role - Agenus; Amgen; AmMax Bio; Arcus Biosciences; AstraZeneca; AVEO; Bayer Health; BeiGene; Boehringer Ingelheim; Bridgebio; Bristol-Myers Squibb/Medarex; Carina Biotech; Clasp Therapeutics; Cytovation; Dewpoint Therapeutics; EMD Serono; Flame Biosciences; Frontier Medicines; Genentech; Harbinger Oncology, Inc; Ikena Oncology; Kestrel Therapeutics; Marengo Therapeutics; Merck; Mirati Therapeutics; Pfizer; Replimune; Revolution Medicines; Roche; SageMedic; SERVIER; Sibylla; T-Cypher Bio; Tachyon Therapeutics; XAIRA Therapeutics; Zentalis; Zentalis
Research Funding - Amgen; Boehringer Ingelheim; BridgeBio; Daiichi Sankyo; EMD Serono; Genentech/Roche; Guardant Health; Lilly; Pfizer; Zentalis
 
Takayuki Yoshino
Honoraria - Chugai Pharma; Merck; MSD K.K.; Takeda
Consulting or Advisory Role - Sumitomo Corp.
Research Funding - Amgen (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); DAIICHI SANKYO COMPANY, LIMITED (Inst); Eisai (Inst); FALCO biosystems Ltd. (Inst); Medical & Biological Laboratories Co., Ltd. (Inst); Merus (Inst); Molecular Health (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Roche (Inst); Sanofi (Inst); Sysmex (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Eric Van Cutsem
Consulting or Advisory Role - Abbvie; Agenus; ALX Oncology; Amgen; Arcus Biosciences; Astellas Pharma; AstraZeneca; Bayer; BeiGene; BioNTech SE; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; Debiopharm Group; Eisai; ElmediX; GlaxoSmithKline; Hookipa Biotech; Incyte; Ipsen; Lilly; Merck KGaA; Merck Sharp & Dohme; Mirati Therapeutics; Nordic Group; Novartis; Pfizer; Pierre Fabre; Roche; Seagen; SERVIER; Simcere; Taiho Pharmaceutical; Takeda; TERUMO
 
Cathy Eng
Consulting or Advisory Role - Abbvie; Amgen (I); California Institute for Regenerative Medicine (CIRM) (I); Hookipa Biotech; IgM Biosciences (I); Merck Serono; Pfizer; Seagen; Taiho Oncology (I); Takeda
Research Funding - Gritstone Bio (Inst); Hutchison MediPharma (Inst); Janssen Oncology (Inst); Merck (Inst); Pfizer (Inst); Sumitomo Dainippon Pharma Oncology (Inst)
Travel, Accommodations, Expenses - Takeda
 
Tae Won Kim
Employment - Asan Medical Center
Research Funding - Genome Insight (Inst); Roche/Genentech (Inst)
 
Harpreet Wasan
Honoraria - Array BioPharma; Celgene; ERYTECH Pharma; Incyte; Merck KGaA; Roche/Genentech; Servier; Sirtex Medical; Zymeworks
Consulting or Advisory Role - Bayer; ERYTECH Pharma; Incyte; Pfizer; Pierre Fabre; Roche Pharma AG; Shire; Sirtex medical
Speakers' Bureau - Celgene; Incyte; Merck KGaA; SERVIER; Sirtex Medical
Research Funding - Merck KGaA (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst); Sirtex Medical (Inst)
Expert Testimony - Oncosil
 
Jayesh Desai
Consulting or Advisory Role - Amgen (Inst); Axelia Oncology; Bayer; BeiGene; Boehringer Ingelheim; Daiichi Sankyo Europe GmbH; Ellipses Pharma; GlaxoSmithKline; Incyte; Merck KGaA; Novartis; Pfizer; Pierre Fabre; Roche/Genentech
Research Funding - Amgen (Inst); AstraZeneca/MedImmune (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Novartis (Inst); Roche (Inst)
 
Fortunato Ciardiello
Consulting or Advisory Role - Amgen; Bayer; Merck KGaA; Pfizer; Roche/Genentech
Research Funding - Amgen (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Ipsen (Inst); Merck KGaA (Inst); Merck Sharp & Dohme (Inst); Roche/Genentech (Inst); SERVIER (Inst); Symphogen (Inst)
 
Rona Yaeger
Consulting or Advisory Role - Loxo@Lilly; Mirati Therapeutics; Revolution Medicines
Research Funding - Boehringer Ingelheim (Inst); Boundless Bio (Inst); Daiichi Sankyo/UCB Japan (Inst); Mirati Therapeutics (Inst); Pfizer (Inst)
 
Timothy Maughan
Consulting or Advisory Role - AstraZeneca; ertex Research Funding - Almac Diagnostics (Inst); Merck KGaA; Pierre Fabre; Pierre Fabre; PsiOxus Therapeutics
Patents, Royalties, Other Intellectual Property - patent pending
 
Elena Beyzarov
Consulting or Advisory Role - Array BioPharma/Pfizer; Mirati Therapeutics; Natera
Research Funding - Boehringer Ingelheim; Mirati Therapeutics; Pfizer
 
Xiaoxi Zhang
No Relationships to Disclose
 
Graham Ferrier
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
Expert Testimony - onco corner
Travel, Accommodations, Expenses - Pfizer
 
Xiaosong Zhang
Employment - Pfizer; Pfizer (I)
Stock and Other Ownership Interests - Pfizer; Pfizer (I)
Patents, Royalties, Other Intellectual Property - Patents in cancer genomics
Travel, Accommodations, Expenses - Pfizer; Pfizer
 
Josep Tabernero
Stock and Other Ownership Interests - 1TRIALSP; Alentis Therapeutics; Oniria Therapeutics; Pangaea Oncology
Consulting or Advisory Role - Accent Therapeutics; Alentis Therapeutics; AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo; F. Hoffmann LaRoche; Genentech; Lilly; Menarini; Merus; MSD; Novartis; Ono Pharmaceutical; Peptomyc; Pfizer; Pierre Fabre; Quantro Therapeutics; Scandion Oncology; Scorpion Therapeutics; Servier; Sotio; Taiho Pharmaceutical; Takeda Pharmaceuticals International AG; Tolremo